Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Long-Term Debt Repayments (2016 - 2025)

Collegium Pharmaceutical (COLL) has 8 years of Long-Term Debt Repayments data on record, last reported at -$48.4 million in Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments fell 400.0% year-over-year to -$48.4 million; the TTM value through Sep 2025 reached $64.6 million, down 43.17%, while the annual FY2024 figure was $107.8 million, 22.23% down from the prior year.
  • Long-Term Debt Repayments reached -$48.4 million in Q4 2025 per COLL's latest filing, down from $16.1 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $113.6 million in Q2 2023 and bottomed at -$48.4 million in Q4 2025.
  • Average Long-Term Debt Repayments over 5 years is $20.4 million, with a median of $16.1 million recorded in 2024.
  • Peak YoY movement for Long-Term Debt Repayments: surged 100.0% in 2022, then tumbled 400.0% in 2025.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $12.5 million in 2021, then soared by 100.0% to $25.0 million in 2022, then dropped by 12.12% to $22.0 million in 2023, then dropped by 26.51% to $16.1 million in 2024, then crashed by 400.0% to -$48.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were -$48.4 million in Q4 2025, $16.1 million in Q3 2025, and $16.1 million in Q2 2025.